KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $1.6 billion.

  • Eli Lilly's Tax Provisions rose 15910.9% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.1 billion, marking a year-over-year increase of 14359.33%. This contributed to the annual value of $5.1 billion for FY2025, which is 14358.85% up from last year.
  • Per Eli Lilly's latest filing, its Tax Provisions stood at $1.6 billion for Q4 2025, which was up 15910.9% from $1.6 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Tax Provisions registered a high of $1.6 billion during Q3 2025, and its lowest value of $113.8 million during Q4 2021.
  • Its 5-year average for Tax Provisions is $481.5 million, with a median of $306.0 million in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first tumbled by 6769.8% in 2021, then skyrocketed by 32583.48% in 2023.
  • Over the past 5 years, Eli Lilly's Tax Provisions (Quarter) stood at $113.8 million in 2021, then soared by 39.46% to $158.7 million in 2022, then surged by 100.95% to $318.9 million in 2023, then soared by 97.08% to $628.5 million in 2024, then soared by 159.11% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.1 billion during Q2 2025.